First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors

Summary

This multicenter, open-label, first-in-human, Phase 1/2 study consists of a Part 1 (Phase 1) open-label dose escalation of EGL-001 administered as a single agent and in combination with an anti-PD(L)-1 treatment, followed by a Part 2 (Phase 2) open-label dose expansion of EGL-001 administered at the RP2D in patients with recurrent and/or metastatic solid tumors as monotherapy and/or combination therapy with anti-PD(L)-1.

Timeline

Start

2024-09-27

Primary completion

2027-01-23

Completion

2027-01-23

Drugs

Indications